As of November 7, 2026, Latigo Biotherapeutics, Inc. is a publicly traded company (Nasdaq: LTGO). The largest holder reporting an active stake on Schedule 13D is Foresite Capital Fund VI LP, at 14.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Beth Seidenberg, a director (19.9%, reporting on Schedule 13G) (Schedule 13D, August 17, 2026).
Is this your company?
About to sign with, pay or invest in Latigo Biotherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Latigo Biotherapeutics, Inc. a real, registered company?
- Latigo Biotherapeutics, Inc. files with the SEC under CIK 2056611 (its SEC filings).
- Its shares are listed under the ticker LTGO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Thousand Oaks, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Latigo Biotherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Dr. Beth C. Seidenberg (filed 2026-10-29).
Who are Latigo Biotherapeutics, Inc.'s owners and officers?
Latigo Biotherapeutics, Inc.: incorporated in Delaware; business address in Thousand Oaks, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Director (Form D, 2025-02-13)
- : Executive Officer (Form D, 2025-02-13)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Ai Biotechnology LLC | 4.8% |
| Schedule 13G, 2026-10-29 | Dr. Beth C. Seidenberg | 19.9% |
| Schedule 13G, 2026-08-18 | Ai Biotechnology LLC | 5% |
| Schedule 13D, 2026-08-17 | Foresite Capital Fund Vi LP | 14.5% |
| Schedule 13G, 2026-08-17 | Ra Capital Management, L.P. | 8.4% |
| Schedule 13G, 2026-08-13 | Deep Track Capital, LP | 7.03% |
Questions about who owns Latigo Biotherapeutics, Inc.
Who owns Latigo Biotherapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Latigo Biotherapeutics, Inc.: Dr. Beth C. Seidenberg (19.9%, Schedule 13G, filed 2026-10-29), Foresite Capital Fund Vi LP (14.5%, Schedule 13D, filed 2026-08-17), Ra Capital Management, L.P. (8.4%, Schedule 13G, filed 2026-08-17) and Deep Track Capital, LP (7.03%, Schedule 13G, filed 2026-08-13).
Who are the largest shareholders of Latigo Biotherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Latigo Biotherapeutics, Inc. on this page are Dr. Beth C. Seidenberg (19.9%), Foresite Capital Fund Vi LP (14.5%) and Ra Capital Management, L.P. (8.4%).
When did Dr. Beth C. Seidenberg buy into Latigo Biotherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Beth C. Seidenberg on this page is the Schedule 13G, filed 2026-10-29, reporting 19.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Latigo Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Latigo Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Latigo Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Latigo Biotherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- 5AM Partners VI, LLC, a 10% owner: 7,325,962 shares (11.0% of shares outstanding), held indirectly through By 5AM Opportunities II, L.P. and 1 other, on a joint filing (Form 4, 2026-08-12).
- 5AM Ventures VI, L.P., a 10% owner: 7,325,962 shares (11.0% of shares outstanding), held indirectly through By 5AM Opportunities II, L.P. and 1 other, on a joint filing (Form 4, 2026-08-12).
- , a 10% owner: 7,325,962 shares (11.0% of shares outstanding), held indirectly through By 5AM Opportunities II, L.P. and 1 other, on a joint filing (Form 4, 2026-08-12).
- 5AM Opportunities II (GP), LLC, a 10% owner: 7,325,962 shares (11.0% of shares outstanding), held indirectly through By 5AM Opportunities II, L.P. and 1 other, on a joint filing (Form 4, 2026-08-12).
- 5AM Opportunities II, L.P., a 10% owner: 7,325,962 shares (11.0% of shares outstanding), held indirectly through By 5AM Opportunities II, L.P. and 1 other, on a joint filing (Form 4, 2026-08-12).
Shares outstanding: 66,299,347 as of 2026-11-02, from the company's latest SEC cover page.
How much has Latigo Biotherapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-13 | $50M | $150M |
Latest IPO step: Latigo Biotherapeutics, Inc. filed its final IPO prospectus, ticker LTGO (424B4, 2026-08-07).
IPO filings: 424B4, 2026-08-07, S-1/A, 2026-08-04, S-1/A, 2026-08-03, S-1, 2026-07-17; ticker LTGO on Nasdaq Global Select Market.
Keep reading
More on Latigo Biotherapeutics, Inc. and the records around it.
Latigo Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Westlake BioPartners Fund I, L.P. also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Kyverna Therapeutics, Inc. (Feb 2026)
- AI Biotechnology LLC also filed stake reports on 3 other companies: Yarrow Bioscience, Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026), Zura Bio Limited (Mar 2026)
- Foresite Capital Fund VI LP also filed stake reports on 4 other companies: IRulya Therapeutics Inc. (Oct 2026), Alumis Inc. (Aug 2026), Verastem, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/latigo-biotherapeutics